How Long Does Dupixent Stay in Your System?
Dupixent (dupilumab) is a monoclonal antibody with a half-life of about 9-17 days in adults, depending on dose, age, and body weight.[1] It typically takes 4-5 half-lives for a drug to be mostly cleared (around 90-95% elimination), so Dupixent remains detectable in the bloodstream for 2-4 months after the last dose.[1][2] Steady-state levels are reached after 10-16 weeks of regular dosing (every 2 or 4 weeks).[1]
Trough concentrations stay above therapeutic levels during standard maintenance dosing, which is why effects can persist weeks after stopping.[3]
When Do Effects Wear Off After Stopping?
Clinical effects from Dupixent often last 4-12 weeks post-discontinuation, varying by condition like atopic dermatitis or asthma.[2][4] Symptoms may rebound gradually as drug levels drop below effective thresholds (around 30-300 mcg/L for most indications).[1] In trials, skin improvements held for 10 weeks after stopping in eczema patients.[4]
Factors Affecting Clearance Time
- Body weight and age: Higher weight or older age shortens half-life slightly (e.g., 10 days in adults over 150kg).[1]
- Liver/kidney function: No dose adjustment needed for mild issues, but severe impairment isn't studied—clearance relies on proteolytic degradation, not organ metabolism.[1][3]
- Dosing regimen: Loading doses (e.g., 600mg) lead to faster steady-state but similar elimination.[1]
- Drug interactions: Minimal; no CYP450 effects, but live vaccines are avoided during treatment.[3]
Pediatric half-life is shorter (8-10 days in kids 6 months+).[1]
Testing for Dupixent in the Body
Blood tests detect Dupixent via ELISA for 3-6 months post-last dose, but it's not routinely monitored outside research.[2] Anti-drug antibodies (in ~10-20% of patients) can accelerate clearance.[1]
Half-Life Compared to Similar Biologics
Dupixent's 2-4 month clearance beats TNF inhibitors like Humira (17-21 days half-life, gone in ~3 months) but matches other IL-4/IL-13 blockers like lebrikizumab (~2 weeks half-life).[5] Unlike small molecules, antibodies aren't filtered by kidneys—they break down intracellularly.
[1]: Dupixent Prescribing Information (FDA, 2024)
[2]: Pharmacokinetics of Dupilumab (Clinical Pharmacology Review)
[3]: Dupixent EMA Summary of Product Characteristics (2024)
[4]: Phase 3 Trial Data: Persistence After Discontinuation (JAAD, 2018)
[5]: DrugBank: Dupilumab vs. Comparators